PMID- 35714626
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20221021
IS  - 1098-9048 (Electronic)
IS  - 1069-3424 (Linking)
VI  - 43
IP  - 5
DP  - 2022 Oct
TI  - Immunotherapy for Asthma.
PG  - 709-719
LID - 10.1055/s-0042-1749454 [doi]
AB  - Asthma represents one of the biggest global health concerns with increasing 
      prevalence and influence on global health. Several distinct asthma phenotypes 
      have been identified with one of the most common, earliest recognized, and 
      described being the allergic asthma phenotype, in which allergens trigger asthma 
      through mechanisms involving allergen-specific immunoglobulin E (IgE). 
      Allergen-specific immunotherapy (AIT), in the forms of subcutaneous immunotherapy 
      (SCIT) and sublingual immunotherapy (SLIT), has been used for many decades as a 
      tool for reducing IgE-mediated sensitization and controlling symptoms of allergic 
      disease, most commonly for allergic rhinitis, and it remains the only currently 
      available disease modifying therapy in atopic patients. AIT has been studied for 
      use in mild to moderate allergic asthma. While the data are often inconsistent, 
      and utilize a multitude of different methods, antigens, and outcome measures, in 
      general, AIT may have several beneficial effects on asthma disease control, 
      quality of life, and requirement for medication. These benefits are notable when 
      immunotherapy is used as an adjunct to pharmacologic treatment in carefully 
      selected and monitored patients with mild to moderate persistent asthma. Patients 
      with severe asthma are excluded from these trials. Importantly, patients with 
      asthma, and in particular severe asthma, may have a higher rate of systemic 
      adverse reactions to SCIT, including anaphylaxis; however, these events are 
      overall rare. Future research in the area is needed to definitively assess the 
      benefit of SCIT and SLIT for patients with asthma, comparing outcomes with 
      different methods, addressing the role of AIT in severe asthma, significance of 
      multiallergen AIT in allergic asthma, and safety concerns in asthma.
CI  - Thieme. All rights reserved.
FAU - Eremija, Jelena
AU  - Eremija J
AD  - Section of Allergy and Immunology, Department of Medicine, Asthma, and Airway 
      Disease Research Center, University of Arizona, Tucson, Arizona.
FAU - Carr, Tara F
AU  - Carr TF
AD  - Section of Allergy and Immunology, Department of Medicine, Asthma, and Airway 
      Disease Research Center, University of Arizona, Tucson, Arizona.
LA  - eng
PT  - Journal Article
DEP - 20220617
PL  - United States
TA  - Semin Respir Crit Care Med
JT  - Seminars in respiratory and critical care medicine
JID - 9431858
RN  - 0 (Allergens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens
MH  - *Asthma/etiology
MH  - Desensitization, Immunologic/adverse effects/methods
MH  - Humans
MH  - Immunoglobulin E
MH  - *Quality of Life
COIS- None declared.
EDAT- 2022/06/18 06:00
MHDA- 2022/10/14 06:00
CRDT- 2022/06/17 18:52
PHST- 2022/06/18 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/06/17 18:52 [entrez]
AID - 10.1055/s-0042-1749454 [doi]
PST - ppublish
SO  - Semin Respir Crit Care Med. 2022 Oct;43(5):709-719. doi: 10.1055/s-0042-1749454. 
      Epub 2022 Jun 17.